Johnson & Johnson Reports Promising Phase 2 Study Results for Multiple Myeloma Treatment, Boosting Stock Price

Johnson & Johnson has reported promising Phase 2 study results for its multiple myeloma treatment, TALVEY and TECVAYLI. The combination of these bispecific antibodies has shown a strong overall response rate and sustained effectiveness in patients with extramedullary disease. The company's Q1 2025 earnings showed a 4.2% increase in worldwide sales to $21.9 billion and a 1.9% increase in adjusted net earnings to $6.7 billion. The effective tax rate rose to 19.3%, and the dividend was increased by 4.8%.

Johnson & Johnson (NYSE: JNJ) recently reported promising results from its Phase 2 study, RedirecTT-1, evaluating the investigational combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) for the treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) patients with true extramedullary disease (EMD). The study, presented at the 2025 European Hematology Association (EHA) Congress, demonstrated a high overall response rate (ORR) of 78.9% and deep, durable responses in patients with this aggressive form of multiple myeloma [1].

The combination of TALVEY® and TECVAYLI®, both first-in-class bispecific antibodies, showed significant efficacy in patients with EMD, where standard therapies often fall short. The study enrolled 90 patients with TCE RRMM and true EMD, of whom 84.4% were triple-class refractory and 35.6% were penta-drug refractory. The combination led to a high ORR of 78.9%, with 54.4% of patients achieving complete response or better [1].

Among responders, 66.2% remained in response at the data cutoff, with a median follow-up of 13.4 months, indicating sustained effectiveness. Furthermore, 61% of patients were progression-free and alive at one year, and 64.1% of patients maintained response for a median duration of 13.8 months [1].

The safety profile of the combination was consistent with previous reports of TALVEY® and TECVAYLI® as monotherapies, with no new safety signals identified. The rates of discontinuation due to adverse events (AEs) were low, with only four participants discontinuing TALVEY® only [1].

In addition to these clinical results, Johnson & Johnson's Q1 2025 earnings report showed a 4.2% increase in worldwide sales to $21.9 billion and a 1.9% increase in adjusted net earnings to $6.7 billion. The effective tax rate rose to 19.3%, and the dividend was increased by 4.8% [2].

References:
[1] https://www.jnj.com/media-center/press-releases/investigational-combination-of-first-in-class-bispecifics-talvey-and-tecvayli-shows-deep-and-durable-responses-in-heavily-pretreated-multiple-myeloma-patients-with-extramedullary-disease
[2] Johnson & Johnson Q1 2025 Earnings Report